Published: Feb. 5, 2026 at 10:56 a.m. ET
Hims & Hers Health launched a cheaper, compounded version of the new Wegovy pill in a move that reignites its competition with Novo Nordisk in the U.S. obesity drug market.
Shares of HIMS rose 11% at market open on Thursday morning, while U.S.-listed shares of Novo Nordisk NVO tumbled 7%.
